Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annu...(actual results todiffer materially from ...),Health

Date:5/8/2008

actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part I, Item IA. "Risk Factors" in Schering-Plough's 2008 Q1 10-Q.

*Olanzapine is marketed as Zyprexa(R) by Eli Lilly

(1) Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of

schizophrenic patients is driven by poor symptom response: a pooled

post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21. Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16375765. (Due to the length of this URL, please copy and paste it into your Internet browser to view)
Accessed on April 8, 2008.

(2) National Institute of Mental Health. Available online at:

http://www.nimh.nih.gov/publicat/bipolar.cfm

(3) Depression and Bipolar Support Alliance (DBSA). Bipolar Disorder Statistics, accessed on May 10, 2007. http://www.dbsalliance.org/site/PageServer?pagename=about_statistics_bipola r (Due to the length of this URL, please copy and paste it into your Internet browser to view)
(4) World Health Organization. WHO European Ministry Conference on Mental

Health. Available online at:

SOURCE Schering-Plough Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet